What is LAM-002A?
LAM-002A is an oral selective kinase inhibitor currently undergoing Phase I trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. These trials seek to evaluate the safety, tolerability, and pharmacokinetics of LAM-002A. Before investigation of LAM-002A in patients with lymphoma, it was studied and found to be safe in patients with psoriasis, rheumatoid arthritis (RA) and Crohn’s disease.
How does LAM-002 work?
Also known as apilimod dimesylate, LAM-002 is a potent and highly selective PIKfyve kinase inhibitor. It is the first compound in this class. Kinases are proteins that modify cell functions. Lymphomas can arise from overactive or high levels of kinases. LAM-002 disrupts the normal activity of this particular kinase, which can lead to death of cancer cells.
What are the side effects?
In previous studies of patients with psoriasis, RA and Crohn’s disease, LAM-002 was well tolerated, with most side effects assessed as mild in severity. The most frequent side effects included headaches, upper respiratory tract infection, and nausea. To date all available nonclinical and clinical data support the safety profile of LAM-002A in patients with non-Hodgkin lymphoma.
How can you access LAM-002A?
LAM-002A is available through a recently opened Phase I trial for men and women with previously-treated B-cell non-Hodgkin lymphoma in the Lymphoma Program at Weill Cornell Medicine.
A full list of trials open at WCM for patients with non-Hodgkin lymphoma is available on our Joint Clinical Trials website.
New Developments in Lymphoma 